went coronary angiography at the time of enrollment (20 who had initial coronary angiograms and significant coronary stenosis (defined as >50% luminal narrowing) and diagnosed with CAD (CAD group), 20 who had initial coronary angiograms but were without significant coronary stenosis (CONT group)), and 15 who had undergone percutaneous coronary intervention 6 months previously and a restenosed coronary vessel was found on their second coronary angiogram (RESTE group). In addition, we also included 20 patients who were undergoing maintenance HD because of end-stage renal disease (HD group). Half of the patients in the HD group were diagnosed as diabetic nephropathy and the rest were chronic glomerular nephritis. Exclusion criteria were acute MI within the past 4 weeks, surgery or trauma within the past month, known malignant diseases, and febrile conditions. Patients with total cholesterol (TC) >220 mg/dl or triglyceride >150 mg/dl were considered to have hyperlipidemia (HL). Patients with systolic or diastolic blood pressure >160 mmHg or >95 mmHg, respectively, or who were under antihypertensive treatment were considered to have hypertension (HT). Patients who were being treated for DM or who had symptoms of DM and a fasting glucose concentration ≥126 mg/dl were considered to have DM. Otherwise, the results of a 75-g oral glucose tolerance test were used to diagnose DM. The study protocol was approved by the institutional review board at Fukuoka University, and written or verbal informed consent was obtained from all of the patients before they entered the study.
Adhesion Molecules
Expression of the following adhesion molecules on neutrophils, monocytes and lymphocytes was measured by flow cytometry (Beckman Coulter Ltd, Luton, UK). Blood samples were anticoagulated with EDTA. Staining was performed in whole blood with fluorescein-isothiocyanate (FITC)-conjugated anti-CD11a (25.3), anti-CD18 (7E4), anti-VLA-4 (HP2/1), anti-ICAM-1 (84H10) and anti-Lselectin (DREG56) monoclonal antibodies (MAbs). Whole blood (100 l) was incubated with saturating concentrations of FITC-conjugated MAbs for 30 min at room temperature. Erythrocytes were lysed and leukocytes were fixed with commercially available solutions (Immunoprep™, Beckman Coulter) by TQ prep Workstation (Beckman Coulter). The cells were then washed with phosphate-buffered saline and immediately subjected to flow cytometric analysis. MAb binding was assessed by flow cytometry equipped with a 488-nm argon laser. To analyze monocytes, lymphocytes and neutrophils, a gate was set in the forward angle versus right angle scatter. The fluorescence intensity of 10,000 events was recorded as the mean channel number over a logarithmic scale of 1-1,026 channels. Results are expressed as the mean channel of fluorescence intensity (Fig 1) . Instrumental optical alignment and fluidics were verified using Flow-Check Fluorospheres (Beckman Coulter), whereas day-to-day variability in instrument settings was monitored and adjusted with the aid of Flow-Set Fluorospheres (Beckman Coulter).
Evaluation of Angiograms
All coronary angiograms were evaluated by a cardiologist who was not aware of any clinical or laboratory details related to the patients. Lesions were classified in accordance with the American College of Cardiology/American Heart Association (ACC/AHA) classification. Significant stenosis or re-stenosis was defined as luminal narrowing of >50%.
Statistical Analysis
Data are shown as the mean ± standard deviation. Categorical variables were compared between groups by a chisquare analysis. Differences in individual variables were analyzed by repeated-measures one-way analysis of variance followed by Fisher's protected least significant difference. A value of p<0.05 was regarded as significant. Data were analyzed using commercially available statistical software (Statview-J 5.0; Abacus Concepts Inc, Calabasus, CA, USA). Table 1 shows the baseline patient characteristics in the 4 groups. Although there were no differences among the groups with regard to the prevalence of HT, DM or HL, the HD group included younger patients, a lower percentage of smokers, and a lower body mass index compared with the CONT group. Although patients had been treated with various combinations of medication, there was no significant difference in the drugs administered, such as angiotensin-converting enzyme, angiotensin-II type 1 receptor antagonists, calcium antagonists, -blockers, long-acting nitrates, and HMG-CoA inhibitors in the CAD and RESTE groups.
Results

Patient Characteristics
Expression of Monocyte Surface Adhesion Molecules
As shown in Fig 2, the CD11a and ICAM-1 expression on monocytes, but not lymphocytes or neutrophils, in the CAD group were significantly higher than in the CONT group. These expressions in the HD and RESTE groups were similar to those in the CONT group. Interestingly, although monocyte CD11a and ICAM-1 expression in the CAD group were significantly higher than in the CONT group, these expressions in the RESTE group were comparable to those in the CONT group.
L-selectin expression on monocytes in the CAD group was also significantly higher than that in the CONT group, but there were no significant differences in CD18 or VLA-4 expression among the groups (Fig 2) . Expression levels of adhesion molecules, (a) CD11a, (b) ICAM-1, (c) CD18, (d) L-selectin and (e) VLA-4 on monocytes in patients without coronary stenosis (CONT group), with initially diagnosed CAD (CAD group), with restenosis (RESTE group) and undergoing HD (HD group). The levels of expression of CD11a and ICAM-1 in the CAD group were significantly higher than those in the CONT group. The expression of these molecules in the RESTE group and HD group were comparable to those in the CONT group. L-Selectin expression in the CAD group was also significantly higher than that in the CONT group. *p<0.05 vs CONT group. CD11a/CD18 and ICAM-1
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Discussion
The main finding of the present study is that patients with initially diagnosed CAD had increased levels of expression of CD11a and ICAM-1 on monocytes. These findings may be important with regard to the potential role of leukocytes in the pathogenesis of atherothrombosis. 21 In fact, leukocyte activation has been associated with increased adherence to the endothelium, 22 increased leukocyte aggregation, and capillary plugging, 23 as well as increased oxidative burst and tissue damage. 24 Thus, the finding of activated leukocytes in patients with CAD is consistent with modern theories regarding the possible detrimental effect that the inflammatory process might have on the development and prognosis of the initial stage of atherosclerosis.
Another important finding is that the levels of expression of CD11a and ICAM-1 on monocytes in patients with restenosed vessels were comparable to those in the CONT group. Although intracoronary stenting has reduced the rate of stenosis, in-stent restenosis, which is almost exclusively caused by neointimal hyperplasia, is still a major clinical problem. 25 Because restenosis is caused by neointimal hyperplasia, the mechanism of stenosis in the CAD group is likely different from that in the RESTE group. Yasukawa et al reported that balloon injury of rat carotid arteries resulted in the strong expression of ICAM-1 on medial smooth muscle cells after 1 and 2 days, and this expression decreased after 5 or 7 days. 26 The expression of ICAM-1 on neointimal smooth muscle cells and regenerating endothelial cells was observed later, at 5 or 7 days after injury. The increased expression of ICAM-1 may be important for inducing restenosis as an initial step after coronary intervention. Because we measured the ICAM-1 level 6 months after coronary intervention in this study, the ICAM-1 level in the RESTE group may return to that in the CONT group.
Treatment of animals with an antibody against ICAM-1 for 6 days resulted in a significant reduction in neointima formation, with no reduction in mononuclear cell infiltration. 26 Although an antibody against CD11a had no effect, suggesting that some CD11a-independent function of ICAM-1 induced neointima proliferation, our findings suggest that some CD11a-dependent function(s) of ICAM-1 may promote the initial stenosis of vessels in humans. Our data are partially consistent with those of Yasukawa et al, and the time-course of treatment suggests that ICAM-1 expression on medial smooth muscle cells is a primary target of the beneficial effects achieved by antibody treatment. 27 In the present study, the levels of expression of monocyte CD11a/CD18 and ICAM-1 in HD patients were similar to those in patients without CAD. In another study, high plasma concentrations of soluble ICAM-1 were observed in HD patients compared with controls. 28 Although these findings must be confirmed by further studies, several theories can be proposed. First, the levels of C-reactive protein in the previous study may have been higher than those in normal subjects. Second, the mechanism of atherosclerosis in HD patients may differ from that in CAD. Fewer biocompatible membranes in dialysis patients leads to a chronic activation of leukocytes, overproduction of proinflammatory cytokines, a sustained production of reactive oxygen/nitrogen species and consumption of antioxidant defenses, which subsequently leads to slow progress of atherosclerosis. 29 Because these mechanisms are chronic, not acute reactions, it may be difficult to find the differences in the expression levels between HD patients and normal subjects.
The expression of L-selectin on monocytes in the CAD group was also significantly higher than that in the CONT group. Although CD11b/CD18 is upregulated and Lselectin is rapidly shed from the leukocyte surface by a proteolytic mechanism after leukocyte activation, 30 an association between CD11a/CD18 and L-selectin has not been reported. Because soluble L-selectin inhibits the adhesion of leukocytes to cytokine-activated endothelial cells, 31 the increased L-selectin expression observed in the present study may be caused by a compensatory effect against the increase in CD11a and ICAM-1-induced adherence.
Study Limitations
This study simply examined the association between adhesion molecules and coronary stenosis. A prospective trial in patients with initial stenosis or restenosis is needed to help demonstrate the potential effects of these adhesion molecules. Although we assessed coronary atherosclerosis by coronary angiography, intravascular ultrasonography should be used to detect significant atheroma in a future study.
Conclusion
We found that the monocyte expression of CD11a and ICAM-1 was normalized in patients with restenosed vessels, but was increased in patients with CAD. However, further studies are needed to complete our knowledge of their roles in the pathology of vascular disease and to promote the development of new therapeutic strategies.
